



Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry

Eric L. Simpson · Ben Lockshin · Lara Wine Lee ·
Zhen Chen · Moataz Daoud · Andrew Korotzer

© The Author(s) 2024

Publisher Correction to: Dermatol Ther (Heidelb) (2024) 14:261–270
<https://doi.org/10.1007/s13555-023-01061-4>

The infographic was missing from this article and should have appeared as below.

The original article can be found online at <https://doi.org/10.1007/s13555-023-01061-4>.

E. L. Simpson (✉)
Department of Dermatology, Oregon Health and Science University, Portland, OR, USA
e-mail: simpsons@ohsu.edu

B. Lockshin
Department of Dermatology, Georgetown University, Washington, DC, USA

L. W. Lee
Medical University of South Carolina, Charleston, SC, USA

Z. Chen · A. Korotzer
Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA

M. Daoud
Sanofi, Cambridge, MA, USA

Infographic

Real-world effectiveness of dupilumab in adult and adolescent patients with atopic dermatitis: 2-year interim data from the PROSE registry

Eric L. Simpson, Ben Lockshin, Lara Wine Lee, Zhen Chen, Moataz Daoud, Andrew Korotzer

OBJECTIVE

Evaluate **2-year** effectiveness of **dupilumab** among patients aged ≥ 12 years with **moderate-to-severe atopic dermatitis (AD)** included in the ongoing, prospective, multi-center, real-world, **PROSE study**.



USA and Canada



Dupilumab





2
Years

RESULTS



632 Patients

Improvements were seen at the first post-baseline clinic visit and **sustained throughout the 2 years** in:



Similar improvements were seen in **BSA affected by AD, POEM and DLQI**.

Consistent and sustained improvements were also seen in the proportion of patients **“very good/excellent”** on the **PGAD** scale.

CONCLUSIONS

In the real-world PROSE registry, patients with moderate-to-severe AD experienced **improvement in disease control, symptoms, and quality of life**, up to 2 years after initiating dupilumab treatment.

Data were consistent with the known safety profile of dupilumab.

Abbreviations: BL, baseline; BSA, Body Surface Area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; PGAD, Patient Global Assessment of Disease; P-NRS, Pruritus Numerical Rating Scale; POEM, Patient-Oriented Eczema Measure.



The graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © The authors, CC-BY-NC 2023.

The original article has been corrected.

Open Access. This article is licensed under a Creative Commons Attribution-Non-Commercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material

in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.